Qi Song

Qi Song

Auto-generated profile, based on publicly available information

Qi Song

State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institute of Biomedical Sciences, Human Phenome Institute, Zhongshan Hospital, Fudan University, Shanghai, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
YLYan Li
Yan Li
CXChen Xu
Chen Xu
BWBing Wang
Bing Wang
FXFujiang Xu
Fujiang Xu
FMFahan Ma
Fahan Ma
CDChen Ding
Chen Ding
Chemotherapy and targeted therapy are the major treatments for gastric cancer (GC), but drug resistance limits its effectiveness. Here, we profile the proteome of 206 tumor tissues from patients with GC undergoing either chemotherapy or anti-HER2-based therapy. Proteome-based classification reveals four subtypes (G-I–G-IV) related to different clinical and molecular features. MSI-sig high GC patients benefit from docetaxel combination treatment, accompanied by anticancer immune response. Further study reveals patients with high T cell receptor signaling respond to anti-HER2-based therapy; while activation of extracellular matrix/PI3K-AKT pathway impair anti-tumor effect of trastuzumab. We observe CTSE functions as a cell intrinsic enhancer of chemosensitivity of docetaxel, whereas TKTL1 functions as an attenuator. Finally, we develop prognostic models with high accuracy to predict therapeutic response, further validated in an independent validation cohort. This study provides a rich resource for investigating the mechanisms and indicators of chemotherapy and targeted therapy in GC.

25 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
LLLingling Li
Lingling Li
DJDongxian Jiang
Dongxian Jiang
QZQiao Zhang
Qiao Zhang
HLHui Liu
Hui Liu
FXFujiang Xu
Fujiang Xu
CDChen Ding
Chen Ding
Esophageal squamous cell carcinoma (ESCC) is malignant while the carcinogenesis is still unclear. Here, we perform a comprehensive multi-omics analysis of 786 trace-tumor-samples from 154 ESCC patients, covering 9 histopathological stages and 3 phases. Proteogenomics elucidates cancer-driving waves in ESCC progression, and reveals the molecular characterization of alcohol drinking habit associated signatures. We discover chromosome 3q gain functions in the transmit from nontumor to intraepithelial neoplasia phases, and find TP53 mutation enhances DNA replication in intraepithelial neoplasia phase. The mutations of AKAP9 and MCAF1 upregulate glycolysis and Wnt signaling, respectively, in advanced-stage ESCC phase. Six major tracks related to different clinical features during ESCC progression are identified, which is validated by an independent cohort with another 256 samples. Hyperphosphorylated phosphoglycerate kinase 1 (PGK1, S203) is considered as a drug target in ESCC progression. This study provides insight into the understanding of ESCC molecular mechanism and the development of therapeutic targets.

18 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
QSQi Song
Qi Song
YYYe Yang
Ye Yang
DJDongxian Jiang
Dongxian Jiang
ZQZhaoyu Qin
Zhaoyu Qin
CXChen Xu
Chen Xu
YHYingyong Hou
Yingyong Hou
Squamous cell carcinoma (SCC) and adenocarcinoma (AC) are two main histological subtypes of solid cancer; however, SCCs are derived from different organs with similar morphologies, and it is challenging to distinguish the origin of metastatic SCCs. Here we report a deep proteomic analysis of 333 SCCs of 17 organs and 69 ACs of 7 organs. Proteomic comparison between SCCs and ACs identifies distinguishable pivotal pathways and molecules in those pathways play consistent adverse or opposite prognostic roles in ACs and SCCs. A comparison between common and rare SCCs highlights lipid metabolism may reinforce the malignancy of rare SCCs. Proteomic clusters reveal anatomical features, and kinase-transcription factor networks indicate differential SCC characteristics, while immune subtyping reveals diverse tumor microenvironments across and within diagnoses and identified potential druggable targets. Furthermore, tumor-specific proteins provide candidates with differentially diagnostic values. This proteomics architecture represents a public resource for researchers seeking a better understanding of SCCs and ACs.

11 June 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
ZQZhaoyu Qin
Zhaoyu Qin
DJDongxian Jiang
Dongxian Jiang
ZYZihan Yu
Zihan Yu
LLLingling Li
Lingling Li
WXWen-Hao Xu
Wen-Hao Xu
CDChen Ding
Chen Ding
Esophageal cancer is one of the most common cancers and a leading cause of cancer-related mortality in the world. Here, we have performed comprehensive characterization of genetic, transcriptomic, proteomic, and phosphoproteomic features in 293 patients with esophageal squamous cell carcinoma (ESCC). Chromosome 12q13.13 amplification was correlated with the up-regulation of Janus kinase–signal transducer and activator of transcription pathway and keratins at the protein level in ESCC tissues and associated with poor prognosis in patients with well-differentiated and moderately differentiated ESCC tumors. Patients with poorly differentiated ESCC tumors had infiltration of activated T cells in the tumor microenvironment, suggesting their potential responsiveness to immunotherapy. Chromosome 8q amplification was associated with lymph node metastasis in ESCC tissues, characterized by a switch from noncanonical to canonical WNT signaling. Proteomic classification revealed that the subgroup with the worst prognosis had chromosome 2p amplification and up-regulated lipid metabolism in ESCC tissues at the protein level. Lipid droplet formation induced by perilipin-2 and apolipoprotein E promoted cytokine secretion, which, in turn, recruited T cells and enhanced stromalization, thereby suppressing T cell activation and promoting malignant ESCC progression. This study provides a resource for understanding the development of ESCC and identifying potential therapeutic targets for testing.